scispace - formally typeset
Search or ask a question
Institution

CSL Behring

Company•Bern, Switzerland•
About: CSL Behring is a company organization based out in Bern, Switzerland. It is known for research contribution in the topics: Hereditary angioedema & Population. The organization has 694 authors who have published 858 publications receiving 19719 citations.
Topics: Hereditary angioedema, Population, Prothrombin complex concentrate, Antibody, Von Willebrand factor
Papers published on a yearly basis
Papers
More filters
Journal Article•DOI•
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

[...]

Felicitas Müller1, Nicola J. Mutch2, Wolfdieter A. Schenk3, Stephanie A. Smith4, Lucie Esterl1, Henri M. H. Spronk5, Stefan Schmidbauer6, William A. Gahl7, James H. Morrissey4, Thomas Renné1 •
Karolinska Institutet1, University of Leeds2, University of Würzburg3, University of Illinois at Urbana–Champaign4, Maastricht University5, CSL Behring6, National Institutes of Health7
11 Dec 2009-Cell
TL;DR: The data identify polyP as a new class of mediator having fundamental roles in platelet-driven proinflammatory and procoagulant disorders, including Hermansky-Pudlak Syndrome patients, who lack platelet polyP.

737 citations

Journal Article•DOI•
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study

[...]

Ravi Sarode1, Truman J. Milling1, Majed A. Refaai2, Antoinette Mangione3, Astrid Schneider4, Billie L. Durn3, Joshua N. Goldstein5 •
University of Texas Southwestern Medical Center1, University of Rochester2, CSL Behring3, CSL Limited4, Harvard University5
10 Sep 2013-Circulation
TL;DR: 4F-PCC is an effective alternative to plasma for urgent reversal of vitamin K antagonist therapy in major bleeding events, as demonstrated by clinical assessments of bleeding and laboratory measurements of international normalized ratio and factor levels.
Abstract: Background—Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin K antagonist reversal. We performed a prospective clinical trial to compare nonactivated 4-f...

622 citations

Journal Article•DOI•
Clinical picture and treatment of 2212 patients with common variable immunodeficiency

[...]

Benjamin Gathmann1, Nizar Mahlaoui2, Laurence Gérard3, Eric Oksenhendler3, Klaus Warnatz1, I. Schulze1, Gerhard Kindle1, Taco W. Kuijpers, Rachel T. van Beem, David Sanchez-Migallon Guzman4, Sarita Workman4, Pere Soler-Palacín5, Javier de Gracia, Torsten Witte, Reinhold E. Schmidt, Jiri Litzman6, Eva Hlaváčková, Vojtech Thon6, Michael Borte7, Stephan Borte7, Stephan Borte8, Dinakantha S. Kumararatne9, Conleth Feighery10, Hilary Longhurst11, Matthew Helbert, Anna Szaflarska, Anna Sediva12, Bernd H. Belohradsky13, Alison Jones14, Ulrich Baumann15, Isabelle Meyts16, Necil Kutukculer17, Per Wågström, Nermeen Galal18, Joachim Roesler, Evangelia Farmaki19, Natalia Zinovieva, Peter Ciznar20, Efimia Papadopoulou-Alataki19, Kirsten Bienemann21, Sirje Velbri22, Z. Panahloo23, Bodo Grimbacher4, Bodo Grimbacher1 •
University of Freiburg1, Paris Descartes University2, Paris Diderot University3, Royal Free Hospital4, Autonomous University of Barcelona5, Masaryk University6, Leipzig University7, Translational Centre for Regenerative Medicine8, Cambridge University Hospitals NHS Foundation Trust9, Trinity College, Dublin10, Barts Health NHS Trust11, Charles University in Prague12, Ludwig Maximilian University of Munich13, Great Ormond Street Hospital14, Hannover Medical School15, Katholieke Universiteit Leuven16, Ege University17, Cairo University18, Aristotle University of Thessaloniki19, Comenius University in Bratislava20, University of Düsseldorf21, Boston Children's Hospital22, CSL Behring23
01 Jul 2014-The Journal of Allergy and Clinical Immunology
TL;DR: In this article, the authors analyzed the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe for Common Variable Immunodeficiency (CVID) patients.
Abstract: Background Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high variability in clinical presentation. The main features include respiratory tract infections and their associated complications, enteropathy, autoimmunity, and lymphoproliferative disorders. Objective This study analyzes the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe. Methods Data on 2212 patients with CVID from 28 medical centers contributing to the European Society for Immunodeficiencies Database were analyzed retrospectively. Results Early disease onset ( Conclusion Patients with CVID are being managed differently throughout Europe, affecting various outcome measures. Clinically, CVID is a truly variable antibody deficiency syndrome.

446 citations

Journal Article•DOI•
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial

[...]

Joshua N. Goldstein1, Majed A. Refaai2, Truman J. Milling3, Brandon Lewis4, Robert Goldberg-Alberts5, Bruce A. Hug5, Ravindra Sarode3 •
Harvard University1, University of Rochester Medical Center2, University of Texas Southwestern Medical Center3, Texas A&M Health Science Center4, CSL Behring5
23 May 2015-The Lancet
TL;DR: 4F-PCC is non-inferior and superior to plasma for rapid INR reversal and effective haemostasis in patients needing VKA reversal for urgent surgical or invasive procedures.

374 citations

Journal Article•DOI•
Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy

[...]

Herbert Schöchl1, Ulrike Nienaber, Marc Maegele, Gerald Hochleitner2, Florian Primavesi, Beatrice Steitz3, Christian Arndt, Alexander A. Hanke4, Wolfgang G. Voelckel, Cristina Solomon3 •
University of Vienna1, CSL Behring2, Salk Institute for Biological Studies3, Hannover Medical School4
04 Mar 2011-Critical Care
TL;DR: TEM-guided haemostatic therapy with fibrinogen concentrate and PCC reduced the exposure of trauma patients to allogeneic blood products.
Abstract: Introduction Thromboelastometry (TEM)-guided haemostatic therapy with fibrinogen concentrate and prothrombin complex concentrate (PCC) in trauma patients may reduce the need for transfusion of red blood cells (RBC) or platelet concentrate, compared with fresh frozen plasma (FFP)-based haemostatic therapy.

371 citations

Authors

Showing all 696 results

NameH-indexPapersCitations
Ralph Weissleder1841160142508
Matthias Nahrendorf9634432492
Mingyao Liu8285431501
Gregory J. Kato6327813121
Marco Ranucci6134811343
Jonathan Leor5522214215
David G. Barnes5018610639
Bernd Hoppe491998094
Blaise Corthésy461307024
Melvin Berger451219547
Jerry S. Powell381096702
Jonathan M. Edelman37887365
Dong-Eog Kim371795483
Charles L. Shear356212279
Sylvia Miescher32962938
Network Information
Related Institutions (5)
Beth Israel Deaconess Medical Center
52.5K papers, 2.9M citations

81% related

Leiden University Medical Center
38K papers, 1.6M citations

81% related

Cincinnati Children's Hospital Medical Center
29.7K papers, 1.1M citations

81% related

St. Jude Children's Research Hospital
19.2K papers, 1.2M citations

81% related

Children's Hospital of Philadelphia
31.8K papers, 1.1M citations

81% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20223
202167
202086
201951
201855
201762